NCT02826642View on ClinicalTrials.gov

A Dose Finding Study of IDH305 With Standard of Care in IDH1 Mutant Acute Myeloid Leukemia

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

August 26, 2016

Primary Completion Date

November 29, 2016

Study Completion Date

November 29, 2016

Conditions
Acute Myeloid Leukemia (AML)
Interventions
DRUG

IDH305

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY